CKDXF (Opthea) Debt-to-Equity : -0.93 (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Opthea Debt-to-Equity?

Opthea's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.04 Mil. Opthea's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $157.21 Mil. Opthea's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $-168.71 Mil. Opthea's debt to equity for the quarter that ended in Dec. 2024 was -0.93.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Opthea's Debt-to-Equity or its related term are showing as below:

CKDXF' s Debt-to-Equity Range Over the Past 10 Years
Min: -14.67 Med: 0 Max: 0.01
Current: -0.93

During the past 13 years, the highest Debt-to-Equity Ratio of Opthea was 0.01. The lowest was -14.67. And the median was 0.00.

CKDXF's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs CKDXF: -0.93

Opthea Debt-to-Equity Historical Data

The historical data trend for Opthea's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opthea Debt-to-Equity Chart

Opthea Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Debt-to-Equity

Get a 7-Day Free Trial

-14.67

-1.87

Opthea Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial															-	-14.67	-	-1.87	-0.93

Competitive Comparison of Opthea's Debt-to-Equity

For the Biotechnology subindustry, Opthea's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Opthea's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opthea's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Opthea's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Opthea Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Opthea's Debt to Equity Ratio for the fiscal year that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.093	+	141.555)	/	-75.81
	=	-1.87

Opthea's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.038	+	157.209)	/	-168.705
	=	-0.93

Opthea (OTCPK:CKDXF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Opthea Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Opthea's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Opthea Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opthea Ltd (OTCPK:CKDXF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

OPT:USA UKJ:Germany OPT:Australia

Address

650 Chapel Street, Level 4, Suite 0403, South Yarra, VIC, AUS, 3141

Website

https://www.opthea.com

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.